<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713815</url>
  </required_header>
  <id_info>
    <org_study_id>Mzhao-004</org_study_id>
    <nct_id>NCT02713815</nct_id>
  </id_info>
  <brief_title>Novel Intervention for Amphetamine-type Stimulants Addiction</brief_title>
  <official_title>Glutamate and γ-aminobutyric Acid (GABA) Deficits in Prefrontal-striatal Circuits: it's Role in Amphetamine-type Stimulants Addiction and Novel Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yunnan Institute For Drug Abuse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The motivational-cognitive psychotherapy and repetitive transcranial magnetic stimulation
      (rTMS) will be used to treat amphetamine-type stimulant (ATS) addiction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Glutamate and GABA deficits in prefrontal-striatal circuits play a vital role in ATS
      addiction and relapse, and proposed motivational-cognitive psychotherapy and repetitive
      transcranial magnetic stimulation (rTMS) as two novel interventions. Focused on evaluating
      Glutamate/GABA functions in prefrontal-striatal circuits, neuropsychological tests,
      biochemical tests, magnetic resonance spectroscopy (MRS) and functional MRI will be used to
      investigate the neurobiological mechanism of ATS addiction and relapse. These methods will
      also be used to evaluate the efficacy of the two novel intervention and investigate the
      mechanisms. The study will be very helpful to develop novel interventions in clinical
      practice and decrease ATS-related harm for both the patients and their families.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Craving for ATS assessed by Visual Analog Scales (VAS) at 12 months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>evaluate all participants' craving for ATS by Visual Analog Scales (VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who relapse</measure>
    <time_frame>12 months</time_frame>
    <description>Follow up with patients after discharge, evaluate number of participants who relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression status assessed by Patient Health Questionnaire-9(PHQ-9)</measure>
    <time_frame>12 months</time_frame>
    <description>evaluate all participants' depression status by Patient Health Questionnaire-9(PHQ-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety status assessed by Generalized Anxiety Disorder Screener (GAD-7)</measure>
    <time_frame>12 months</time_frame>
    <description>evaluate all participants' anxiety status by Generalized Anxiety Disorder Screener (GAD-7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function assessed by CogState Battery (CSB)</measure>
    <time_frame>12 months</time_frame>
    <description>evaluate all participants' cognitive function by the computerized CogState Battery (CSB) Chinese version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response inhibition function assessed by stop signal reaction time task(SSRT)</measure>
    <time_frame>12 months</time_frame>
    <description>evaluate all participants' response inhibition function by stop signal reaction time task(SSRT)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Amphetamine Addiction</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham repetitive transcranial magnetic stimulation (rTMS) of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rTMS group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use randomized, prospective pseudo stimulus controlled clinical trial design, evaluation of repetitive transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>psychotherapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The main content of motivational-cognitive psychotherapy is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rTMS+psychotherapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination therapy by using rTMS and motivational-cognitive psychotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>repetitive transcranial magnetic stimulation (rTMS)</intervention_name>
    <description>Stimulate the dorsomedial prefrontal cortex for 24 weeks by Theta-burst stimulation (TBS), once a day for the first 8 weeks and twice a week for the last 16 weeks</description>
    <arm_group_label>rTMS group</arm_group_label>
    <arm_group_label>rTMS+psychotherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>sham repetitive transcranial magnetic stimulation (rTMS)</intervention_name>
    <description>Stimulate the dorsomedial prefrontal cortex for 24 weeks by sham Theta-burst stimulation (TBS), once a day for the first 8 weeks and twice a week for the last 16 weeks, with the coil set at 90° against the skull</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>motivational-cognitive psychotherapy</intervention_name>
    <description>self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training</description>
    <arm_group_label>psychotherapy group</arm_group_label>
    <arm_group_label>rTMS+psychotherapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In accordance with the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
             for methamphetamine (MA) use disorders

          -  Junior high school degree or above

          -  Normal vision and hearing

          -  Dextromanual

          -  Less than one month before last drug use

        Exclusion Criteria:

          -  Have a disease that affect cognitive function such as history of head injury,
             cerebrovascular disease, epilepsy, etc

          -  Have cognitive-promoting drugs in the last 6 months

          -  Other substance abuse or dependence in recent five years (except nicotine)

          -  Mental impairment, Intelligence Quotient (IQ) &lt; 70

          -  Mental disorders

          -  Physical disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhao Min, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhao Min, PhD</last_name>
    <phone>021-54252689</phone>
    <email>18017311005@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Gaojing Compulsory Rehabilitation Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201900</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ding Xu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>October 15, 2017</last_update_submitted>
  <last_update_submitted_qc>October 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amphetamine-type stimulants</keyword>
  <keyword>prefrontal-striatal circuits</keyword>
  <keyword>Glutamate/GABA</keyword>
  <keyword>motivational and cognitive intervention</keyword>
  <keyword>rTMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
    <mesh_term>Amphetamine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Central Nervous System Stimulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

